NIKKEI 225
29,058.79+183.56(+0.64%)HANG SENG
29,262.45+379.99(+1.32%)CRUDE OIL
73.51+0.21(+0.29%)
Relief Therapeutics Holding AG (0QKQ.L)
| Previous close | 0.2080 |
| Open | 0.2080 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.2080 - 0.2120 |
| 52-week range | 0.2080 - 0.2120 |
| Volume | 299,840 |
| Avg. volume | N/A |
| Market cap | 132.495M |
| Beta (5Y monthly) | -22.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0030 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM21.06.2021 / 07:00 Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large MajorityGeneva, Switzerland, June 21, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announce
- EQS Group
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study results16.06.2021 / 07:00 Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19Geneva, Switzerland, June 16, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical developmen
- EQS Group
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous02.06.2021 / 07:00 Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration Geneva, Switzerland, June 2, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical developmen
